Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GGH | Q92820 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368694 | 0.91 | AKR1B1 (0.34) | FOLH1 | |
| SCHEMBL2368125 | 0.88 | FOLH1 (0.37) | FOLH1CYP1A2GGHGRM3NAALAD2 | |
| SCHEMBL1373642 | 0.80 | FOLH1 (0.42) | FOLH1CYP1A2GGHGRM3NAALAD2 | |
| SCHEMBL2368445 | 0.78 | GGH (0.41) | FOLH1CYP1A2GGHGRM3NAALAD2 | |
| SCHEMBL2368606 | 0.77 | FOLH1 (0.36) | FOLH1CYP1A2GGHGRM3NAALAD2 | |
| SCHEMBL2368450 | 0.76 | FOLH1 (0.38) | FOLH1CYP1A2GGHGRM3NAALAD2 | |
| SCHEMBL2368594 | 0.76 | HDAC3 (0.44) | FOLH1 | |
| SCHEMBL2368127 | 0.76 | TET2 (0.35) | FOLH1CYP1A2GGHGRM3NAALAD2 | |
| SCHEMBL1373663 | 0.75 | FOLH1 (0.41) | FOLH1GGHGRM3NAALAD2 | |
| SCHEMBL2368602 | 0.75 | FOLH1 (0.38) | FOLH1CYP1A2GGHGRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091693-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2024-09-17 | — | — | US | disclosed |
| US-20220098564-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2022-03-31 | — | — | US | disclosed |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2020-09-10 | — | — | US | disclosed |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011106639-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098564-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
| US-12091693-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CYP1A2 4797/4885GGH 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.